Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Deal Watch: Takeda Continues Transaction Spree With Four More Deals

Executive Summary

Takeda's recent deals include a license in Asian for Tesaro's PARP inhibitor Zejula. Meanwhile, Japanese rival Mitsubishi Tanabe is paying roughly $1bn to acquire Israel's NeuroDerm.


Related Content

Start-Up Quarterly Statistics: Fundraising Fell, But Deal-Making Rose In Q3
Takeda-Advinus R&D Alliance ‘Closed’
Pfizer Hits Pause On M&A To See How US Tax Reform Plays
Fosun’s Gland Acquisition Faces Indian Wall?
The PARP Combo Race Is On: Clovis And Bristol Partner On Rubraca
A Whopper Of A Deal: AZ Hands Half Of Lynparza To Merck
Will Mitsubishi's High Offer Price For CNS Target NeuroDerm Deter Others?
US FDA Shows Relaxed Approach On Personalized Medicine In Zejula Approval
NeuroDerm Makes Progress On Simplified Path To Parkinson's Approval
Gilead Buys Nimbus NASH Drug To Dominate Another Liver Disease


Related Companies

Related Deals




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts